Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Tetralogic Pharmaceuticals Corp to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Tetralogic Pharmaceuticals Corp and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tetralogic Pharmaceuticals Corp 0 0 0 0 N/A
Tetralogic Pharmaceuticals Corp Competitors 166 554 1216 16 2.55

As a group, “Biotechnology” companies have a potential upside of 54.16%. Given Tetralogic Pharmaceuticals Corp’s rivals higher probable upside, analysts clearly believe Tetralogic Pharmaceuticals Corp has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Tetralogic Pharmaceuticals Corp and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Tetralogic Pharmaceuticals Corp N/A -$21.14 million -0.02
Tetralogic Pharmaceuticals Corp Competitors $224.58 million $58.11 million -1.04

Tetralogic Pharmaceuticals Corp’s rivals have higher revenue and earnings than Tetralogic Pharmaceuticals Corp. Tetralogic Pharmaceuticals Corp is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are held by insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Tetralogic Pharmaceuticals Corp has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp’s rivals have a beta of 1.13, indicating that their average stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Tetralogic Pharmaceuticals Corp and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tetralogic Pharmaceuticals Corp N/A N/A -73.81%
Tetralogic Pharmaceuticals Corp Competitors -912.91% -186.15% -28.31%

Summary

Tetralogic Pharmaceuticals Corp rivals beat Tetralogic Pharmaceuticals Corp on 5 of the 9 factors compared.

About Tetralogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.